Provided by Tiger Fintech (Singapore) Pte. Ltd.

Outlook Therapeutics, Inc.

1.57
+0.09006.08%
Post-market: 1.570.00000.00%18:42 EDT
Volume:351.28K
Turnover:546.53K
Market Cap:50.27M
PE:-0.39
High:1.57
Open:1.50
Low:1.50
Close:1.48
Loading ...

Outlook Therapeutics files to sell 7.07M shares of common stock for holders

TIPRANKS
·
01 Mar

Outlook Therapeutics Inc - FDA Decision Expected Within Six Months

THOMSON REUTERS
·
28 Feb

Outlook Therapeutics® Re-Submits Biologics License Application for Ons-5010 as a Treatment for Wet Amd to the U.S. Food and Drug Administration

THOMSON REUTERS
·
28 Feb

Outlook Therapeutics Inc : Guggenheim Cuts Target Price to $10 From $12

THOMSON REUTERS
·
19 Feb

Outlook Therapeutics Is Maintained at Neutral by Chardan Capital

Dow Jones
·
18 Feb

Outlook Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $3 From $30

THOMSON REUTERS
·
18 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
18 Feb

Outlook Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
14 Feb

BRIEF-Outlook Therapeutics Reports Financial Results For First Quarter Of 2025

Reuters
·
14 Feb

Outlook Therapeutics Inc -Qtrly Shr $0.72

THOMSON REUTERS
·
14 Feb

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

THOMSON REUTERS
·
14 Feb

Outlook Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview

Reuters
·
10 Feb

BRIEF-Outlook Therapeutics Inc - Enters Securities Purchase Agreement With Avondale Capital

Reuters
·
01 Feb

Outlook Therapeutics Inc - Issues Unsecured Convertible Promissory Note of $33.1 Million

THOMSON REUTERS
·
01 Feb

Outlook Therapeutics Inc - Enters Securities Purchase Agreement With Avondale Capital

THOMSON REUTERS
·
01 Feb

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

THOMSON REUTERS
·
31 Jan